Vimarsana
Biggest News Aggregation in the World

Page 12 - Michael Strapazon News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Michael Strapazon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Michael Strapazon Today - Breaking & Trending Today

New Pilot Program Aims To Improve Quality Of Post-fracture Care In Patients With Osteoporosis - Vimarsana News

New Pilot Program Aims To Improve Quality Of Post-fracture Care In Patients With Osteoporosis

/PRNewswire/ -- The National Osteoporosis Foundation (NOF) today announced a collaboration with Medstar Health in Maryland and Atrium Health in North Carolina...

Amgen Announces New Data Highlighting Global Trends In Hip Fracture Incidence And Treatment - Vimarsana News

Amgen Announces New Data Highlighting Global Trends In Hip Fracture Incidence And Treatment

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Amgen Announces New Data Highlighting Global Trends In Hip Fracture Incidence And Treatment - Vimarsana News

Amgen Announces New Data Highlighting Global Trends In Hip Fracture Incidence And Treatment

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from real-world data in Asia, Europe, Oceania, and North and South America on the temporal trends...

Amgen Announces New Data Highlighting Global Trends In Hip Fracture Incidence And Treatment - Vimarsana News

Amgen Announces New Data Highlighting Global Trends In Hip Fracture Incidence And Treatment

Amgen today announced results from real-world data in Asia Europe Oceania, and North and South America on the temporal trends in hip fracture incidence, and in post-fracture pharmacological treatment intervention. The study, presented as a late-breaking abstract at the American Society for Bone and Mineral Research 2021 Annual Meeting is titled " Hip Fractures: Initial Report of Trends in Incidence, Treatment, and ...

Amgen And Kyowa Kirin Present Positive Late-Breaking Data From Phase 2 Study Of AMG 451/KHK4083 In Adult Patients With Moderate-to-Severe Atopic Dermatitis At EADV Congress - Vimarsana News

Amgen And Kyowa Kirin Present Positive Late-Breaking Data From Phase 2 Study Of AMG 451/KHK4083 In Adult Patients With Moderate-to-Severe Atopic Dermatitis At EADV Congress

/PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) today announced that positive data from a Phase 2 study of AMG 451/KHK4083 were...